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Abstract
Background In patients with heart failure with reduced ejection fraction (HFrEF) on sub-optimal doses of beta-blockers, 
it is conceivable that changes in heart rate following treatment intensification might be important regardless of underlying 
heart rhythm. We aimed to compare the prognostic significance of both achieved heart rate and change in heart rate following 
beta-blocker uptitration in patients with HFrEF either in sinus rhythm (SR) or atrial fibrillation (AF).
Methods We performed a post hoc analysis of the BIOSTAT-CHF study. We evaluated 1548 patients with HFrEF (mean age 
67 years, 35% AF). Median follow-up was 21 months. Patients were evaluated at baseline and at 9 months. The combined 
primary outcome was all-cause mortality and heart failure hospitalisation stratified by heart rhythm and heart rate at baseline.
Results Despite similar changes in heart rate and beta-blocker dose, a decrease in heart rate at 9 months was associated with 
reduced incidence of the primary outcome in both SR and AF patients [HR per 10 bpm decrease—SR: 0.83 (0.75–0.91), 
p < 0.001; AF: 0.89 (0.81–0.98), p = 0.018], whereas the relationship was less strong for achieved heart rate in AF [HR per 
10 bpm higher—SR: 1.26 (1.10–1.46), p = 0.001; AF: 1.08 (0.94–1.23), p = 0.18]. Achieved heart rate at 9 months was only 
prognostically significant in AF patients with high baseline heart rates (p for interaction 0.017 vs. low).
Conclusions Following beta-blocker uptitration, both achieved and change in heart rate were prognostically significant 
regardless of starting heart rate in SR, however, they were only significant in AF patients with high baseline heart rate.
Keywords Heart failure · Heart rate · Atrial fibrillation · Beta-blockers
Introduction
Heart rate is a risk factor in patients with heart failure with 
reduced ejection fraction (HFrEF) that, when reduced, pro-
vides outcome benefits [1, 2]. However, the benefit of heart 
rate-mediated reduction is less clear in atrial fibrillation 
(AF). Studies in patients with HFrEF and AF have provided 
conflicting results, with some suggesting that elevated heart 
rate is associated with adverse outcome in HFrEF patients 
in AF, while others found no significant relationship [3–5]. 
Conceptually, reducing heart rate should have prognostic 
benefit in HFrEF patients in AF. Randomised controlled tri-
als evaluating rate control strategies in patients with AF have 
only included small numbers of patients with HFrEF [6]. 
Additionally, very few studies have evaluated the importance 
of changes in heart rate over time [7, 8]. Despite the lack of 
data, current guidelines recommend an optimal heart rate 
between 60 and 100 bpm in patients with AF and HFrEF, 
while studies evaluating rate control in patients with AF (but 
not necessarily HFrEF) suggest that rates up to 110 bpm may 
be acceptable [6, 9].
One strategy for reducing heart rate is the use of beta-
blockers, a mainstay of therapy in HFrEF [9, 10]. Although 
beta-blockers are prognostically beneficial in patients with 
HFrEF, it is unclear whether the beta-blocker-mediated 
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reduction in heart rate directly affects prognosis, with several 
studies reporting conflicting results [11–17]. Furthermore, 
questions have recently been raised about the prognostic 
benefits of beta-blocker therapy in HFrEF patients with 
AF [18, 19]. In particular, there is very little information 
about whether increasing beta-blocker therapy in patients 
on sub-optimal doses might derive greater benefit from 
any associated heart rate reduction [20]. Despite the cur-
rent uncertainty over the benefits of beta-blockers in HFrEF 
patients in AF, current guidelines recommend uptitration of 
beta-blocker therapy to the same target doses irrespective of 
the underlying heart rhythm.
To the best of our knowledge, the relative effects of 
change in heart rate following intensification of beta-blocker 
therapy have not been previously examined. Given the fre-
quent co-existence of AF and HFrEF, it is important to deter-
mine whether patients in AF derive the same benefit from 
heart rate reduction and beta-blocker uptitration as those in 
SR, and whether this effect is modulated by changes in beta-
blocker dose. We utilised the systems BIOlogy Study to Tai-
lored Treatment in Chronic Heart Failure (BIOSTAT-CHF) 
dataset to compare the prognostic importance of changes 
in heart rate following beta-blocker uptitration in HFrEF 
patients in AF versus those in sinus rhythm (SR).
Methods
Patient selection
The BIOSTAT-CHF study design has been published previ-
ously [21]. Briefly, BIOSTAT-CHF was a large European, 
multi-center, multi-national, prospective, observational 
study of 2516 patients with new onset or worsening HF 
with either a left ventricular ejection fraction (LVEF) of 
≤ 40% or plasma concentrations of Brain Natriuretic Peptide 
(BNP) > 400 pg/ml and/or N-terminal pro Brain Natriuretic 
Peptide (NT-proBNP) > 2000 pg/ml, who were being treated 
with furosemide ≥ 40 mg/day (or equivalent) and were on 
≤ 50% of the target dose of angiotensin-converting enzyme 
inhibitor (ACEI)/angiotensin II receptor blocker (ARB) or 
beta-blocker therapy. Patients were recruited from both the 
in-patient and out-patient settings. Patients were classified as 
having AF if they had AF on their electrocardiogram (ECG) 
at their baseline visit and were reclassified at the second 
visit ECG. We excluded patients with paced or undetermined 
ECG rhythms and those with LVEF ≥ 40%.
In the first 3 months after recruitment, treating clinicians 
aimed to initiate and/or uptitrate ACEI/ARBs and beta-
blockers to recommended target doses which have been pre-
viously published by the European Society of Cardiology 
[22]. Reasons for failure to successfully uptitrate and side 
effects have been previously published [23]. Following the 
3-month uptitration period, patients entered a 6-month main-
tenance period where no further uptitration was mandated 
unless clinically indicated. Patients then were invited for a 
second visit at 9 months. The trial was approved by the local 
ethics committee of the participating centers and all patients 
provided written informed consent. The study complied with 
the Declaration of Helsinki.
Clinical outcomes
Heart rate and rhythm were assessed by ECG with all 
patients supine and rested for at least 5 min. In BIOSTAT-
CHF, all patients were followed up for clinical outcomes. 
After the scheduled visits at baseline and 9 months, patients 
were contacted by telephone every 6 months.
The primary outcome for this study was the combined 
endpoint of all-cause mortality or HF hospitalisation. HF 
hospitalisation was determined as admission to hospi-
tal ≥ 24 h due to worsening HF requiring either intravenous 
or increased dose of oral diuretics.
Statistical analysis
Clinical, ECG and echocardiographic data was obtained at 
baseline, with clinical and ECG data obtained at 9 months. 
Normally distributed continuous variables were reported as 
mean ± SD and categorical data, as number with percentage 
in brackets. Comparisons between continuous variables were 
carried out using a two-tailed Student t test and categori-
cal variables were tested using the Chi square test. Heart 
rate and beta-blocker dose at baseline and 9 months were 
analysed for their association with the primary outcome 
and all-cause mortality using the Cox proportional hazard 
model and Kaplan–Meier analysis. Competing risks regres-
sion with death as a competing risk was used to determine 
hazard ratios for hospitalisation alone. To adjust for treat-
ment indication bias inverse probability weighting was used, 
the method of which has been explained in detail previously 
[23]. Variables included in the inverse probability weighting 
were age, baseline heart rate and country of origin.
Variables were tested for univariable significance and 
were then included in a multivariable model with the BIO-
STAT-CHF risk score [23] to assess their independent asso-
ciation with outcome. SR and AF patients were evaluated 
separately and interaction testing between SR and AF was 
also performed within the whole cohort. Heart rate in incre-
ments of 10 bpm and beta-blocker dose as a percentage of 
target dose were examined. Increments of 12.5% of target 
beta-blocker dose were chosen to reflect clinically used dos-
ages—for example, bisoprolol has a target dose of 10 mg, 
and is commonly increased in doses of 1.25 mg (12.5% of 
target dose). Nine-month outcomes only included patients 
who did not have an event in the first 9 months and those 
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who had ECG data available. Correlations were assessed 
using Pearson correlation. A p value < 0.05 was considered 
significant throughout. Statistical analysis was performed 
using R version 3.4.1.
Results
Baseline characteristics
The baseline characteristics of the BIOSTAT-CHF study 
have been reported previously [21]. Median follow-up in 
BIOSTAT-CHF was 21 months. Derivation of the cohort for 
this study is shown in Fig. 1. In total, following exclusion of 
patients with LVEF ≥ 40% and paced or undetermined ECG 
rhythms, we included 1548 patients from the BIOSTAT-
CHF index cohort (Table 1). 535 patients (34.6%) were in 
AF on their baseline ECG.
Relationship between baseline heart rate 
and outcome
In total, the primary outcome occurred in 554 patients 
[35.8% of the total cohort; 323 (31.8%) in SR and 231 
(43.2%) in AF], including 324 deaths [20.9% of the total 
cohort; 212 (18.6%) in SR and 112 (28.0%) in AF] and 337 
hospitalisations [21.8% of the total cohort; 198 (19.5%) in 
SR and 139 (26.0%) in AF] (Table 2).
Baseline heart rate was not a significant predictor of the 
primary outcome in SR patients (HR per 10 bpm higher: 
1.02 95% CI 0.96–1.08, p = 0.60), however, higher baseline 
heart rate was significantly associated with improved out-
come in patients with AF (HR per 10 bpm higher: 0.91; 
95% CI 0.86–0.96, p = 0.001; p for interaction vs. sinus 
rhythm 0.011). There were no significant associations for 
the individual endpoints of mortality and HF hospitalisa-
tion (Table 2).
Relationship between achieved heart rate 
at 9 months, change in heart rate at 9 months 
and outcome
ECGs at the 9-month visit were available for 1155 patients. 
198 patients died prior to their 9 month visit, while 195 
patients did not have an ECG available. After exclusion of 
125 patients with paced rhythms, 1030 patients remained for 
analysis, of which 734 (71.3%) were in sinus rhythm and 296 
(28.7%) were in AF. Heart rate-lowering medication use at 
9 months is shown in Table 3. AF at the 9-month ECG was 
associated with increased likelihood of the primary outcome 
compared to SR when added to the BIOSTAT risk prediction 
model (HR 1.63; 95% CI 1.18–2.23, p = 0.003).
Mean achieved heart rate at 9 months was significantly 
lower in SR patients compared to AF (67 ± 13 versus 
81 ± 18 bpm, respectively, p < 0.001). Higher baseline 
heart was significantly associated with a greater reduc-
tion in heart rate at 9 months (r = − 0.77, p < 0.001) and 
an increase in beta-blocker dose at 9 months (r = 0.12, 
p < 0.001). After adjustment for the BIOSTAT risk predic-
tion model and likelihood of uptitration, a higher achieved 
heart rate at 9 months was significantly associated with 
increased likelihood of the primary outcome in SR 
Fig. 1  Cohort derivation. Derivation of the cohort from the BIOSTAT-CHF study
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patients (HR 1.26 per 10 bpm higher; 95% CI 1.10–1.46, 
p = 0.001) but not in AF (HR 1.08 per 10 bpm higher; 
95% CI 0.94–1.23, p = 0.18, p for interaction vs. SR 0.26) 
(Table 4). There were no significant associations between 
achieved heart rate and the individual endpoints.
There was no significant difference in change in 
heart rate at 9 months between SR and AF patients 
(− 11.5 ± 21.9 bpm versus − 9.1 ± 25.9 bpm, respectively; 
p = 0.12). In multivariable analysis, a decrease in heart rate 
was significantly associated with reduced likelihood of the 
primary outcome in both SR and AF (SR: HR 0.83 per 
10 bpm decrease; 95% CI 0.75–0.91, p < 0.001; AF: HR 
0.89 per 10 bpm decrease; 95% CI 0.81–0.98, p = 0.018, p 
for interaction vs. SR 0.97) (Table 4). A decrease in heart 
rate at 9 months was also significantly associated with 
reduced HF hospitalisation in patients in SR (HR 0.88 per 
10 bpm decrease; 95% CI 0.77–1.00, p = 0.046).
Effects of changes in heart rate in patients stratified 
by baseline heart rate
Among the patients assessed at 9 months, baseline heart 
rate was 77 bpm in those in SR and 85 bpm in those in 
AF. Higher achieved heart rate and change in heart rate 
were significantly associated with outcome regardless of 
baseline heart rate in sinus rhythm (Fig. 2), however, a 
different pattern was seen in patients in AF however, with 
higher achieved heart rate only being associated with worse 
Table 1  Baseline cohort 
characteristics according to 
heart rhythm at baseline
Bold values indicate p < 0.05
32 patients (2.1%) did not have NYHA class recorded
SBP systolic blood pressure, DBP diastolic blood pressure, COPD chronic obstructive pulmonary disease, 
ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, LVEF left ventricular 
ejection fraction, NT-proBNP N-terminal pro B-type natriuretic peptide
a Median (interequartile range)
Total cohort (n = 1548) Sinus rhythm 
(n = 1013)
Atrial fibrillation 
(n = 535)
p value 
between SR 
and AF
Age (years) 67 ± 12 65 ± 13 71 ± 10 < 0.001
Men 1175 (75.9) 750 (74.0) 425 (79.4) 0.018
SBP (mmHg) 124 ± 21 124 ± 21 124 ± 21 0.55
DBP (mmHg) 76 ± 12 75 ± 12 76 ± 12 0.14
Heart rate (bpm) 83 ± 21 78 ± 17 93 ± 24 < 0.001
QRS duration (ms) 112 ± 29 113 ± 29 112 ± 28 0.56
NYHA  classa < 0.001
 I 37 (2.4) 30 (3.0) 7 (1.3)
 II 557 (36.7) 400 (40.5) 157 (29.7)
 III 734 (48.4) 448 (45.3) 286 (54.2)
 IV 188 (12.4) 110 (11.1) 78 (14.8)
Ischaemic aetiology 718 (47.4) 510 (51.4) 208 (39.8) < 0.001
Hypertension 935 (60.4) 609 (60.1) 326 (60.9) 0.76
Current smoker 252 (16.3) 201 (19.9) 51 (9.6) < 0.001
Diabetes mellitus 490 (31.7) 322 (31.8) 168 (31.4) 0.88
COPD 259 (16.7) 163 (16.1) 96 (17.9) 0.35
Renal impairment 357 (23.1) 193 (19.1) 165 (30.8) < 0.001
ACEI/ARB 1158 (74.8) 770 (76.0) 388 (72.5) 0.13
Beta-blocker 1299 (83.9) 853 (84.2) 446 (83.4) 0.67
Beta-blocker dose % < 0.001
 0 250 (16.1) 161 (15.9) 89 (16.6)
 1–49 938 (60.6) 644 (63.6) 294 (55.0)
 50–99 292 (18.9) 176 (17.4) 116 (21.7)
 ≥ 100 68 (4.4) 32 (3.2) 36 (6.7)
MRA 860 (55.6) 575 (56.8) 285 (53.3) 0.19
Digoxin 284 (18.3) 86 (8.5) 198 (37.0) < 0.001
LVEF (%) 27.3 ± 6.9 27.1 ± 7.0 27.8 ± 6.9 0.07
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outcome in patients with higher baseline heart rates (base-
line heart rate > 85 bpm: HR 1.37 per 10 bpm higher; 95% 
CI 1.16–1.61, p < 0.001; ≤ 85 bpm: HR 0.99 per 10 bpm 
higher; 95% CI 0.80–1.22, p = 0.94, p for interaction 0.017) 
(Fig. 2). A similar pattern was seen with change in heart rate.
Discussion
In this multi-national, multi-centre contemporary study of HF 
patients with left ventricular systolic dysfunction on sub-opti-
mal doses of beta-blocker therapy subjected to treatment inten-
sification, we found that both achieved heart rate and change in 
heart rate at 9 months are strongly associated with outcome in 
HFrEF patients in SR regardless of baseline resting heart rate. 
In contrast, only a decrease in heart rate was significantly asso-
ciated with improved outcome in AF patients, and in particular 
only in those with higher baseline heart rates.
HF and AF frequently co-exist and present an additional 
layer of complexity in management [24]. Established mark-
ers of prognosis, such as baseline heart rate, and established 
therapies such as beta-blockers, appear to be less effective 
in HF patients in AF compared to those in SR. Our results 
align with the increasing evidence from observational stud-
ies [3, 4], randomised controlled trials [7] and meta-analysis 
[5] that suggests that baseline heart rate is not an important 
prognostic marker in HFrEF patients in AF. Very few stud-
ies however have examined the prognostic significance of 
follow-up heart rate in patients with HFrEF in SR and in 
AF, particularly in the setting of treatment change. Culling-
ton et al. found that heart rate at 1 year was a significant 
independent predictor of outcome in SR patients but not in 
AF [3], while in contrast, in an analysis of the Candesar-
tan in heart failure: assessment of reduction in mortality 
and morbidity (CHARM) programme, Vazir et al. found 
that change in heart rate was also an independent predic-
tor of poor outcome in both SR and AF patients, although 
the prognostic significance was less in AF patients [7]. Our 
study differs from these, however, as we have evaluated a 
cohort of patients who were not receiving target doses of 
beta-blockers. A recent large meta-analysis of beta-blocker 
HF trials reported that a lower achieved heart rate was asso-
ciated with improved outcome only in SR patients [25]. It is Ta
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Table 3  Heart rate controlling medication prescription at 9 months
Sinus rhythm (734) Atrial 
fibrillation 
(296)
Beta-blocker 691 (94.1) 276 (93.2)
Digoxin 208 (28.3) 201 (67.9)
Verapamil/diltiazem 8 (1.1) 8 (2.7)
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noteworthy that many of these beta-blocker trials were con-
ducted in patients that had not been treated with contempo-
rary heart failure therapy. Our study provides new evidence 
involving contemporary clinical practice.
A major part of our study was to examine the effect of 
a change in heart rate in conjunction with changes in beta-
blocker dose. We found that despite similar reductions in 
heart rate and similar increase in beta-blocker dose, the prog-
nostic significance of both achieved and changes in heart rate 
were only seen in AF patients at higher baseline heart rates. 
It is not completely clear why heart rate reduction using 
beta-blockers should not be associated with improved out-
come in HFrEF patients in AF regardless of baseline heart 
rate, as it is in SR. It has been postulated that higher heart 
rates in patients with AF is beneficial to compensate for the 
loss of atrial ejection and reduced left ventricular diastolic 
filling [26]. It may also be that reduction in heart rate using 
increased dosages of beta-blockade is not a beneficial strat-
egy, perhaps due to the potential for ventricular pauses that 
might be associated with adverse outcome [27].
Table 4  Cox regression analyses of achieved heart rate and change in heart rate at 9 months on clinical outcomes
Bold values indicate p < 0.05
BIOSTAT-CHF risk prediction model for mortality and HF hospitalisation includes: age, HF hospitalisation in the previous year, peripheral 
oedema, systolic blood pressure, NT-proBNP, haemoglobin, HDL cholesterol, sodium, beta-blocker use at baseline
BIOSTAT-CHF risk prediction model for heart failure hospitalisation alone: age, previous HF hospitalisation, presence of oedema, systolic 
blood pressure and estimated glomerular filtration rate
BIOSTAT-CHF risk prediction model for mortality alone: age, blood urea nitrogen, NT-proBNP, haemoglobin and beta-blocker use at baseline
a Adjusted for likelihood of uptitraton and BIOSTAT-CHF risk prediction model
b Competing risk of death
Sinus rhythm (n = 734) Atrial fibrillation (n = 296) Inter-
action 
p 
value
Number of events (%) Multivariable 
hazard ratio (95% 
CI)
p value Number of events (%) Multivariable 
hazard ratio (95% 
CI)
p value
Achieved heart rate; hazard ratio per 10 bpm  highera
 Mortality or heart failure 
hospitalisation
168 (22.9) 1.29 (1.10–1.46) 0.001 115 (38.9) 1.08 (0.94–1.23) 0.18 0.26
 Mortality 1.00 (0.87–1.15) 0.96 1.02 (0.88–1.18) 0.77 0.20
 HF  hospitalisation+ 1.07 (0.91–1.27) 0.42 0.84 (0.65–1.07) 0.16 0.99
Change in heart rate; hazard ratio per 10 bpm  decreasea
 Mortality or heart failure 
hospitalisation
168 (22.9) 0.83 (0.75–0.91) < 0.001 115 (38.9) 0.89 (0.81–0.98) 0.018 0.97
 Mortality 0.95 (0.88–1.03) 0.23 0.92 (0.84–1.02) 0.11 0.50
 HF  hospitalisationb 0.88 (0.77–1.00) 0.046 0.93 (0.85–1.01) 0.10 0.91
Fig. 2  The relationship between achieved heart rate and change in 
heart rate at 9 months stratified by baseline heart rate. Association 
of achieved heart rate (left) and change in heart rate (right) with the 
primary outcome in sinus rhythm and atrial fibrillation stratified by 
baseline heart rate above and below the median
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We found however that there were benefits in targeting 
heart rate in AF patients with higher baseline heart rate. A 
common clinical question in treatment of HFrEF in patients 
AF is whether the AF is secondary to HF or vice versa [28]. 
It may be that in some HFrEF patients in AF, the presence 
of AF may be a reflection of HF severity [29]. However, it 
is also possible that the AF is driving the HF, and that con-
trol of the heart rate in this setting (“tachycardiomyopathy”) 
might improve HF outcome [30]. This might also explain our 
somewhat surprising finding that increased baseline heart 
rate was significantly associated with improved outcome fol-
lowing treatment intensification over 9 months. Being aware 
of the fact that the median heart rate was significantly higher 
in patients with AF at baseline, we noted that a higher base-
line heart rate was significantly associated with an increase 
in beta-blocker dose (i.e., more likelihood of uptitration) and 
a greater reduction in heart rate at 9 months. While we can-
not determine causality due to the nature of our study, this 
does suggest that potentially some of these patients at higher 
baseline heart rate may have benefited from intensified ther-
apy and may reflect an element of “tachycardiomyopathy”. 
While it is often difficult to diagnose tachycardiomyopathy 
prospectively, this might account for this unexpected finding.
Heart rate reduction by other mechanisms generally 
appears to have limited benefit in AF-HFrEF patients. 
Digoxin is, at best, neutral in terms of clinical outcome 
in AF patients with HFrEF, though it might provide some 
symptomatic benefit, while non-dihyrdopyridine calcium 
channel blockers are contra-indicated in HF [31]. Alterna-
tive strategies may be more beneficial. There may be a role 
for AV nodal ablation and cardiac resynchronisation device 
implantation, however, no large randomised trials have been 
conducted to confirm this as yet [32]. Another strategy that 
has been proposed is AF ablation with recent data reporting 
improved outcomes in patients with AF and HFrEF [33]. 
Indeed, these results are particularly prescient given the 
recent results of the CASTLE-AF trial [33], as they suggest 
that persisting with beta-blocker dose uptitration to maximal 
targets with the aim of lowering heart rate may not provide 
any mortality benefit in HFrEF patients in AF, and perhaps 
other strategies such as pulmonary vein isolation or pace-
maker implantation and AV node ablation may prove to have 
more prognostic benefit to remove the burden of AF.
Our study has some limitations. First, this is a post hoc 
analysis of a prospective study. However, one of the strengths 
of the study was that as well as being an observational study, 
the protocol also mandated uptitration of HF therapy, thus 
adding some of the benefits of a clinical trial element. Sec-
ond, we only obtained resting heart rhythm and rate at two 
separate time points. It is possible that patients may have 
been in paroxysmal AF at the time of their visit, while in 
SR the majority of time in the interim or vice versa. Further 
insights into the effect of heart rate on prognosis may have 
been obtained by more frequent heart rate monitoring. Third, 
we did not have any information on changes in heart rate or 
beta-blocker dose beyond 9 months, which might have had 
an impact on clinical outcomes. Additionally, despite the 
overall size of this study, there were a relatively low number 
of patients in AF at 9 months, thus we cannot exclude that 
interactions may have become significant with larger num-
bers. Further studies specifically examining beta-blocker 
uptitration are required to confirm these findings. Finally, 
due to the number of patients, we did not further stratify 
the cohort based on cardio-selectivity of prescribed beta-
blocker. Larger cohorts should be evaluated with the specific 
aim of determining whether heart rate reduction mediated 
by cardio-selective beta-blockers is more beneficial in AF 
patients with HFrEF.
Conclusions
In HFrEF patients in SR both achieved and change in heart 
rate following beta-blocker uptitration were associated with 
improved outcomes, regardless of heart rate at baseline.
Despite a similar increase in beta-blocker dose and base-
line heart rate reduction in HFrEF patients in AF, achieved 
and decrease in heart rate from baseline were only prognosti-
cally significant in patients with higher baseline heart rates.
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